Cargando…
Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors
The aim of this study was to determine risk factors for adverse events (AE)-related treatment discontinuation and severe anemia among patients with chronic hepatitis C virus (HCV) genotype 1 infection, treated with first-generation protease inhibitor (PI)-based therapy. We included all patients who...
Autores principales: | Miotto, N., Mendes, L.C., Zanaga, L.P., Goncales, E.S.L., Lazarini, M.S.K., Pedro, M.N., Goncales, F.L., Stucchi, R.S.B., Vigani, A.G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Brasileira de Divulgação Científica
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926529/ https://www.ncbi.nlm.nih.gov/pubmed/27356107 http://dx.doi.org/10.1590/1414-431X20165300 |
Ejemplares similares
-
Transient elastography and APRI score: looking at false positives and false negatives. Diagnostic performance and association to fibrosis staging in chronic hepatitis C
por: Mendes, L.C., et al.
Publicado: (2016) -
Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
por: Zanaga, L.P., et al.
Publicado: (2016) -
All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response
por: Miotto, Noelle, et al.
Publicado: (2018) -
Recurrent hepatitis C treatment with direct acting antivirals – a real life study at a Brazilian liver transplant center
por: Zanaga, L.P., et al.
Publicado: (2019) -
Survival benefits of interferon-based therapy in patients with recurrent
hepatitis C after orthotopic liver transplantation
por: Zanaga, L.P., et al.
Publicado: (2017)